secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001437749-25-019868
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025
--------------------------------------------------------------------------------

- Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
- Shares outstanding post-offering: 8,976,914.
- EXXUA is first-in-class oral 5HT1a receptor agonist for MDD; no sexual dysfunction warning; studied in >5,000 patients.
- Conference call June 11, 2025 at 4:30 p.m. ET to detail EXXUA commercialization plan.
- Net proceeds for working capital and to fund EXXUA launch; expects FDA-approved product to enter $22B U.S. MDD market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019868/0001437749-25-019868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019868/aytu20250609_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer